Feedback
Adenosine Deaminase, RBC
0083001
Ordering Recommendation

May be used as a marker of severe combined immunodeficiency (SCID); lack of adenosine deaminase (ADA) allows deoxyadenosine to accumulate and kill lymphocytes.

Mnemonic
ADA
Methodology
Kinetic Spectrophotometry
Performed
Sun, Tue, Thu
Reported
1-4 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).  
Specimen Preparation
Do not freeze. Transport 1 mL whole blood.  
Storage/Transport Temperature
Refrigerated.  
Unacceptable Conditions
Hemolyzed specimens.  
Remarks
 
Stability
Ambient: 15 days; Refrigerated: 15 days; Frozen: Unacceptable  
Reference Interval
Effective August 20, 2012

400-900 mU/g Hb
Interpretive Data
Adenosine Deaminase (ADA) deficiency is an autosomal recessive disorder of purine metabolism primarily affecting lymphocyte development, viability, and function. Affected individuals have less than 1 percent of normal ADA catalytic activity in red cell hemolysates. ADA deficiency is the cause of 20-30 percent of SCID cases. If the patient has been recently transfused, ADA deficiency may be masked; interpret results with caution. Heterozygotes cannot be identified by this test. If clinical suspicion remains, consider testing to determine the ADA genotype: Severe Combined Immunodeficiency (SCID) Panel, Sequencing and Deletion/Duplication, 19 Genes (ARUP test code 2010219).


Note
CPT Code(s)
84311
Components
Component Test Code*Component Chart NameLOINC
0083001Adenosine Deaminase RBC47549-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • ADA